alexa Tetraploidy: A New Marker for Breast Cancer?
ISSN: 2157-2518
Journal of Carcinogenesis & Mutagenesis

Like us on:

Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
  • Commentary   
  • J Carcinog Mutagen 2013, Vol 4(3): 145
  • DOI: 10.4172/2157-2518.1000145

Tetraploidy: A New Marker for Breast Cancer?

Jaroslava Halper*
Department of Pathology, College of Veterinary Medicine and Medical Partnership, The University of Georgia, Athens, GA 30602, USA
*Corresponding Author: Jaroslava Halper, Department of Pathology, College of Veterinary Medicine and Medical Partnership, The University of Georgia, Athens, GA 30602, USA, Email: [email protected]

Received Date: Jun 19, 2013 / Accepted Date: Jun 27, 2013 / Published Date: Jul 10, 2013

In this issue Sennerstam and Strömberg are reporting on the occurrence of polyploidization in breast cancer [1]. In particular, they are concerned about tetraploidy as a phenomenon occurring at two points of breast carcinogenesis: as an intermediate state, when it is still reversible (as in precancerous stage), or when the tumor reaches certain size and is on the way to aneuploidy, and genomic instability. So it is important to distinguish between the “benign”, precancerous and the more ominous, leading to genomic instability tetraploidy. The authors show that this is feasible using a parameter reflecting genomic instability and proliferative activity (Stemline Scatter Index, or SSI) on a consecutive sample of 519 breast cancer patients collected over a period of 17 years which allowed follow up of patients.

How can this be applied in practice? As it is widely known, evaluation of breast carcinoma for the presence or absence of several markers has become routine and it is an important component of determination how treatment modalities and protocols should be individualized for each particular patient with a specific profile of markers. Besides histologic grade and staging, testing for estrogen receptors and HER2 has become pretty much routine. Mutations in BRCA1 and BRCA2 genes have been known to play important roles in the pathogenesis of breast cancer, and molecular profiling assays looking at a variety of genes, including BRCAs are quickly becoming another useful tool to determine an optimal course of therapy. As far as tetraploidy is concerned according to Jonsdottir et al. it is significantly more frequent in BRCA2-mutated than sporadic breast carcinomas, and it is confined to luminal type of tumors rather than to tumors bearing triple-negative phenotype [2]. The authors hypothesize that BRCA2 mutations facilitate polyploidisation through cytokinesis failure as well as through creation of chromosome bridges [2], however, they do not discuss the presence of “benign” reversible tetraploidy. Tetraploid cells are usually eliminated by immunological means which can be potentially enhanced by suitable chemotherapy [3]. Again, the assumption here is that these cells are on the way to aneuploidy. However, one can speculate.

Circulating breast tumor cells could also be a source of tetraploid cells as many of them give rise to metastases [4], so it might be even more essential to apply SSI assessment to this subset of tumor cells.

What is your experience? We woud like to hear about it so please share it with us either in the form of a research report or a clinical study!


Citation: Halper J (2013) Tetraploidy: a New Marker for Breast Cancer? J Carcinogene Mutagene 4: 145. Doi: 10.4172/2157-2518.1000145

Copyright: © 2013 Halper J. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Leave Your Message 24x7